Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has completed the pilot phase of their previously announced partnership with Novo Nordisk to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the companies will now move into the development phase to make a more effective production process. Achieving this first milestone included extensive modification and testing of a microbial expression s...